Tony Sedgwick
Tony is Advisor to the Board and an Innova Partnerships Associate. He adopts a hands-on approach, working closely with companies to develop the business model and business plan. Tony is currently Chairman of Innova Biosciences Ltd, Chairman of Plastid AS (Norway), CEO of Novacta Biosystems Ltd and advisor to the University of Auckland.
Tony's career has covered a range of entrepreneurial roles in the biotech and pharmaceutical industries. In 2005, Tony was appointed Chief Executive of DanioLabs Ltd, a Cambridge University spin-out. Under Tony's leadership DanioLabs became a neurology/ ophthalmology-focussed pharmaceutical reprofiling company. DanioLabs was acquired by Summit plc in March 2007 for £15 million. From 2002 to 2005, Tony was Chief Executive of Cambridge Biotechnology Ltd ("CBT"), a Parke Davis/Cambridge University spin-out. CBT developed a portfolio of product candidates in the areas of pain, obesity and inflammation. In March 2005, CBT was acquired by Biovitrum AB of Stockholm.
Prior to his move into biotechnology, Tony had a long and successful clinical development career at Roche, where has was Global Head of Clinical Operations and UK Development Director.
Back to the Team Page